These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34253649)

  • 21. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
    Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF;
    Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
    Morand EF; Isenberg DA; Wallace DJ; Kao AH; Vazquez-Mateo C; Chang P; Pudota K; Aranow C; Merrill JT
    Rheumatology (Oxford); 2020 Oct; 59(10):2930-2938. PubMed ID: 32107560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M; Magder LS
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treat to target in systemic lupus erythematosus].
    Mucke J; Düsing C; Chehab G; Schneider M
    Z Rheumatol; 2020 May; 79(4):351-358. PubMed ID: 32232548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.
    Wang M; Gladman DD; Ibañez D; Urowitz MB
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):833-7. PubMed ID: 22290935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.
    Samões B; Zen M; Abelha-Aleixo J; Gatto M; Doria A
    Autoimmun Rev; 2022 Oct; 21(10):103165. PubMed ID: 35931316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort.
    Saccon F; Zen M; Gatto M; Margiotta DPE; Afeltra A; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Frontini G; Moroni G; Dall'Ara F; Tincani A; Signorini V; Mosca M; Frigo AC; Iaccarino L; Doria A
    Ann Rheum Dis; 2020 Jul; 79(7):943-950. PubMed ID: 32321721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort.
    Elera-Fitzcarrald C; Reátegui-Sokolova C; Gamboa-Cárdenas RV; Medina M; Zevallos F; Pimentel-Quiroz VR; Zeña-Huancas PA; Pastor-Asurza CA; Perich-Campos RA; Rodríguez-Bellido ZJ; Alarcón GS; Ugarte-Gil MF
    Lupus; 2020 Oct; 29(12):1644-1649. PubMed ID: 32741305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
    Poomsalood N; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
    Lupus; 2019 Sep; 28(10):1189-1196. PubMed ID: 31307256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Determinant Factors of Morbidity in Patients with Systemic Lupus Erythematosus].
    Jacinto M; Silva E; Riso N; Moraes-Fontes MF
    Acta Med Port; 2017 May; 30(5):368-372. PubMed ID: 28865500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients.
    Perea-Seoane L; Agapito-Vera E; Gamboa-Cardenas RV; Guzmán-Sánchez G; Pimentel-Quiroz VR; Reategui-Sokolova C; Medina M; Elera-Fitzcarrald C; Noriega E; Rodriguez-Bellido Z; Pastor-Asurza C; Perich-Campos R; Alarcón GS; Ugarte-Gil MF
    Lupus; 2022 Jan; 31(1):110-115. PubMed ID: 34969318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and cost-effectiveness of a multicomponent intervention to implement a clinical practice guideline for systemic lupus erythematosus: protocol for a cluster-randomized controlled trial.
    Trujillo-Martín MM; Ramallo-Fariña Y; Del Pino-Sedeño T; Rúa-Figueroa Í; Trujillo-Martín E; Vallejo-Torres L; Imaz-Iglesia I; Sánchez-de-Madariaga R; de Pascual-Medina AM; Serrano-Aguilar P;
    BMC Health Serv Res; 2019 Nov; 19(1):783. PubMed ID: 31675957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of the Asia Pacific Lupus Collaboration cohort.
    Kandane-Rathnayake R; Golder V; Louthrenoo W; Luo SF; Jan Wu YJ; Li Z; An Y; Lateef A; Sockalingam S; Navarra SV; Zamora L; Hamijoyo L; Katsumata Y; Harigai M; Chan M; O'Neill S; Goldblatt F; Hao Y; Zhang Z; Al-Saleh J; Khamashta M; Takeuchi T; Tanaka Y; Bae SC; Lau CS; Hoi A; Nikpour M; Morand EF
    Int J Rheum Dis; 2019 Mar; 22(3):425-433. PubMed ID: 30398013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis.
    Sun F; Zhang D; Wang H; Wang H; Liu Z; Geng S; Wang X; Li T; Wan W; Lu L; Teng X; Morel L; Ye S
    Clin Exp Rheumatol; 2022 Sep; 40(9):1733-1737. PubMed ID: 34874833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus.
    Elefante E; Tani C; Stagnaro C; Ferro F; Parma A; Carli L; Signorini V; Zucchi D; Peta U; Santoni A; Raffaelli L; Mosca M
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32075876
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial.
    Olsen NJ; James JA; Arriens C; Ishimori ML; Wallace DJ; Kamen DL; Chong BF; Liao D; Chinchilli VM; Karp DR
    Trials; 2018 Dec; 19(1):694. PubMed ID: 30572906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treat to target in systemic lupus erythematosus: a commentary.
    Ugarte-Gil MF; Burgos PI; Alarcón GS
    Clin Rheumatol; 2016 Aug; 35(8):1903-1907. PubMed ID: 27406378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.